APRE Aprea Earnings per share for the last twelve months

APRE (Aprea Therapeutics Inc.) - company brandmark

Demand for targeted oncology therapy remains colossal due to the complexity of genetic mutations. Aprea Therapeutics (APRE) is developing an ecosystem of drugs to combat DNA damage, creating closed treatment protocols. The rolling net income per share trend demonstrates that the parameter value reaches -0.70. Supply stability is ensured here by strict climate control during the transportation of medications.

APRE (Aprea Therapeutics) Net earnings per share for the last 12 months history from 07/04/2022 to 11/14/2026

Aprea Therapeutics - analytical breakdowns and key metrics (APRE)

- current quotes and average value forecast:
Price Chart Aprea|APRE - Average Forecast Price
- market capitalization data:
Market Value Aprea Therapeutics|APRE - Business Value
- shareholders' equity book value data:
Book Value per Share Aprea Therapeutics|APRE - Company Net Assets|Market Value to Book Value Ratio aprea.com|APRE - Company Assets
- debt burden and liquidity indicators:
Debt to Equity Aprea Therapeutics|APRE - Long-Term Debt to Equity|Short-Term Debt to Equity Aprea|APRE - Company Cumulative Debt|Debts to Book Capitalization Aprea|APRE - Long-Term Indebtedness|Company Current Liabilities Aprea Therapeutics|Quick Liquidity Indicator aprea.com
- net income and valuation multiples indicators:
APRE - Final Profit|Future Profit Aprea Therapeutics|APRE - Market Price to Net Income Ratio|Forward P/E Multiple Aprea Therapeutics, Inc.|APRE - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Aprea Therapeutics, Inc.|APRE - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Aprea Therapeutics|APRE - Earnings per share for the trailing year|Quarterly EPS earnings growth aprea.com|APRE - Earnings growth in current year|Net earnings per share growth forecast for next year Aprea Therapeutics
- revenue and sales details:
APRE - Company Annual Revenue|Company Future Sales Volume Aprea|APRE - Price to Sales|Forward P/S Multiple Aprea Therapeutics Inc.
Basic company analysis:Aprea Therapeutics Inc. (APRE)
Mass-produced product of Aprea

Operational business resilience is determined by the ability to generate real income per unit of shareholder equity. This metric aggregates annual net income, excluding the impact of total issuance to assess actual profitability. For Aprea Therapeutics (APRE), which is protected by the humanitarian status of oncology research in the US, this indicator reflects the efficiency of R&D expenditures. By analyzing the change in EPS over 12 months, an investor assesses the risk of capital freeze amid market stagnation.

Analysis of competing companies

INCY - Earnings per share for the last twelve months|HCM (HUTCHMED) - Earnings per share for the last 12 months|Nuvation Bio Inc. (NUVB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DAWN|MNPR (monopartx.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months inhibrx.com (INBX)|Earnings per share for the last twelve months I-Mab (IMAB)|FENC - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Heron Therapeutics Inc HRTX|Nuvectis Pharma, Inc - Earnings per share for the last twelve months|CHRS - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Corbus Pharmaceuticals|CRDF: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BeyondSpring Pharma BYSI|Net earnings per share for the last 12 months BCAB|Net earnings per one share for the last twelve months Lixte Biotechnology LIXT|Net earnings per share for the last 12 months CTXR (Citius Pharmaceuticals Inc.)|CLRB (Cellectar Biosciences, Inc.) - Earnings per share for the trailing year|BioLineRx Ltd. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters CANF (Can-Fite BioPharma Ltd.)|Kazia Therapeutics Limited - Net earnings per share (EPS TTM)|Earnings per share for the trailing year SLXN (silexion.com)|NCNA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months chimerix.com (CMRX)|Earnings per share for the last twelve months Cyclacel|GTHX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) KRON|Net earnings per share (EPS TTM) Kintara Pharma (KTRA)|Earnings per share for the last twelve months Oncternal ONCT|PRTG (Portage Biotech) - Earnings per one share for the last 12 months